Delivery Order SPE2DR25D1007-SPE2DR26FY9AA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $11,850.55 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pen injectors. The contract was executed on February 2, 2026, with an ultimate completion date of February 3, 2026, and utilized firm fixed-price pricing with no set-aside designation. Performance will occur at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $2,812.74 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pen injections on January 14, 2026. This is a firm fixed-price, non-set-aside delivery order with a completion date of January 15, 2026, to be performed at the awardee's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $13,854.10 to AmerisourceBergen Drug Corp for Zepbound 15 mg/0.5 ml pen injectors, with an ultimate completion date of January 15, 2026. This is a firm fixed-price delivery order with no set-aside designation, executed as a competitive award. The place of performance is listed as Conshohocken, Pennsylvania, which serves as the company's corporate headquarters. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc. (doing...
- The Defense Logistics Agency awarded a $10,348.16 delivery order to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injectors on January 16, 2026, with an ultimate completion date of January 20, 2026. This competitively awarded, firm fixed-price contract with no set-aside designation is being fulfilled at the company's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp operates as a subsidiary of Cencora, Inc., a major pharmaceutical distributor...
- The Defense Logistics Agency awarded a $2,831.16 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 mL pen injections, with a completion date of February 3, 2026. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $25,216.32 firm fixed-price delivery order to AmerisourceBergen Drug Corp (subsidiary of parent company Cencora, Inc.) on January 8, 2026, for the supply of Zepbound 5 mg/0.5 mL pen injectors. The contract, with an ultimate completion date of January 9, 2026, will be fulfilled at the awardee's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation, demonstrating AmerisourceBergen's capability to...
- The Defense Logistics Agency awarded a $18,939.21 delivery order to AmerisourceBergen Drug Corp for Zepbound 2.5 mg/0.5 ml pen injections, with a completion date of January 2, 2026. This is a firm fixed price, non-set-aside contract awarded on December 31, 2025, with performance at AmerisourceBergen's Conshohocken, Pennsylvania location. The award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical,...
- The Defense Logistics Agency awarded a $4,273.44 firm fixed price delivery order to AmerisourceBergen Drug Corp on August 15, 2025, for the supply of Zepbound 10 mg/0.5 mL pen injectors with an ultimate completion date of August 18, 2025. This is a non-set-aside competitive award leveraging AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion global pharmaceutical support vehicle that runs through December 2026....
- The Defense Logistics Agency awarded a $10,187.80 delivery order to AmerisourceBergen Drug Corp on January 30, 2026, for the supply of Zepbound 7.5 mg/0.5 ml pen injections. This is a firm fixed-price, competitively awarded contract with no set-aside designation, scheduled for completion by February 2, 2026. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's parent company Cencora, Inc.'s...
- The Defense Logistics Agency awarded a delivery order valued at $1,607.32 to AmerisourceBergen Drug Corp for the supply of Zepbound 5 mg/0.5 mL pen injectors (0.5 mL) on January 7, 2026, with completion required by January 8, 2026. This is a firm fixed-price delivery order with no set-aside designation, awarded competitively under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The product will be delivered to...
- SPE2DR25D1007Indefinite Delivery Contract
- SPE2DR25D1007-SPE2DR26FY9AADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,157.06 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 mL pen injectors on February 3, 2026, with an ultimate completion date of February 4, 2026. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical. The IDC, valued at up to $999,999,999.00 and extending through December 2031, serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a broad range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement needs, particularly for military and veteran healthcare systems. The company's performance under this delivery order supports DLA's medical supply chain operations and demonstrates its ongoing capability to fulfill government contracts for essential pharmaceutical commodities required by military treatment facilities and other federal medical institutions. Zepbound, a diabetes medication, aligns with AmerisourceBergen's established portfolio of delivering endocrinology and specialty pharmaceutical products to federal customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 2/2/26 |